Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 2/20 | 0.31 |
| ▸ | EDNRB | P24530 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 3/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.31 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30033560 | 0.72 | BRPF1 (0.44) | BRPF1EDNRA | |
| SCHEMBL12405339 | 0.70 | BRPF1 (0.57) | BRPF1EDNRAEDNRB | |
| SCHEMBL27978057 | 0.70 | XIAP (0.38) | — | |
| SCHEMBL28734412 | 0.70 | BRPF1 (0.40) | BRPF1MTORPIK3CARPTORMLST8 | |
| SCHEMBL17813461 | 0.68 | BRPF1 (0.42) | BRPF1MTORPIK3CARPTORMLST8 | |
| SCHEMBL27975731 | 0.68 | RPS6KA3 (0.37) | — | |
| SCHEMBL12807167 | 0.67 | KCNH2 (0.40) | BRPF1 | |
| SCHEMBL21039035 | 0.67 | BRPF1 (0.41) | BRPF1 | |
| SCHEMBL22207509 | 0.67 | BRPF1 (0.41) | BRPF1EDNRAEDNRB | |
| SCHEMBL27978052 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | BRPF1 1186/4885EDNRA 1617/4885EDNRB 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.